Shearman & Sterling advised the underwriters in the offering. Mazanti advised Y-mAbs Therapeutics.rY-mAbs Therapeutics, Inc. executed its 2,804,878 shares of common stock at a public offering price…
Y-mAbs Therapeutics’ $115 Million Follow-On Public Offering
